ECSP066507A - MODULATORS OF P-SELECTINE GLICOPROTEIN BINDING PSGL- I - Google Patents

MODULATORS OF P-SELECTINE GLICOPROTEIN BINDING PSGL- I

Info

Publication number
ECSP066507A
ECSP066507A EC2006006507A ECSP066507A ECSP066507A EC SP066507 A ECSP066507 A EC SP066507A EC 2006006507 A EC2006006507 A EC 2006006507A EC SP066507 A ECSP066507 A EC SP066507A EC SP066507 A ECSP066507 A EC SP066507A
Authority
EC
Ecuador
Prior art keywords
cell
glicoprotein
selectine
modulators
cells
Prior art date
Application number
EC2006006507A
Other languages
Spanish (es)
Inventor
Rong-Hwa Lin
Chung Nan Chang
Original Assignee
Abgenomics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/662,906 external-priority patent/US20040116333A1/en
Application filed by Abgenomics Corp filed Critical Abgenomics Corp
Publication of ECSP066507A publication Critical patent/ECSP066507A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Los compuestos multiméricos que se uno a P-Selectina Glicoproteina 1 (PSGL-1) sobre la superficie de las células T or natural killer (NK) cells pueden ser usadas para inducir a la célula T o la agotamiento de la céula NK y/o para inducir a la célula T o la apoptosis de la célula NK. Los compuestos multiméricos y métodos de la invención pueden ser usados para controlar las células T no deseadas o las inmuno respuestas mediadas por la célula NK en condiciones, tales como enfermedades inflamatorias, enfermedades autoinmunes, rechazo de transplantes y enfermedades alérgicas.Multimeric compounds that bind P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and / or to induce T cell or NK cell apoptosis. The multimeric compounds and methods of the invention can be used to control unwanted T cells or immune responses mediated by the NK cell under conditions, such as inflammatory diseases, autoimmune diseases, transplant rejection and allergic diseases.

EC2006006507A 2003-09-15 2006-04-13 MODULATORS OF P-SELECTINE GLICOPROTEIN BINDING PSGL- I ECSP066507A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/662,906 US20040116333A1 (en) 2001-08-03 2003-09-15 Modulators of P-selectin glycoprotein ligand 1

Publications (1)

Publication Number Publication Date
ECSP066507A true ECSP066507A (en) 2006-10-10

Family

ID=36242362

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006507A ECSP066507A (en) 2003-09-15 2006-04-13 MODULATORS OF P-SELECTINE GLICOPROTEIN BINDING PSGL- I

Country Status (16)

Country Link
EP (1) EP1663290A4 (en)
JP (1) JP5808879B2 (en)
KR (1) KR101159140B1 (en)
CN (1) CN1852730B (en)
AU (1) AU2004273807B2 (en)
BR (1) BRPI0414402A (en)
CA (1) CA2538284C (en)
EC (1) ECSP066507A (en)
IL (1) IL174172A (en)
NO (1) NO20061306L (en)
NZ (1) NZ546203A (en)
RU (1) RU2407539C2 (en)
SG (1) SG146670A1 (en)
TW (2) TW201012472A (en)
UA (1) UA91004C2 (en)
ZA (1) ZA200602151B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0510561A (en) * 2004-05-11 2007-11-20 Abgenomics Corp epitopes that induce t cell death
WO2009139459A1 (en) * 2008-05-15 2009-11-19 国立大学法人 岡山大学 Method for prevention and treatment of metabolic syndrome through the inhibition of psgl-1
WO2017120534A1 (en) * 2016-01-08 2017-07-13 Bioalliance C.V. Tetravalent anti-psgl-1 antibodies and uses thereof
CN115887659A (en) * 2022-11-23 2023-04-04 中山大学附属第七医院(深圳) Identification and application of terminally exhausted T cell population "TCF19+PD1+TIM3+CD8+"
CN121108302A (en) * 2025-09-22 2025-12-12 渼达(广州)生物科技有限公司 A recombinant protein of recombinant human Fc and P-selectin, its detection product, preparation method and application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI903489A7 (en) * 1988-11-11 1990-07-10 Medical Res Council Ligands containing one moiety, receptors containing these ligands, methods for their preparation and uses of the ligands and receptors
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
ZA973051B (en) * 1996-04-24 1998-10-12 Genentech Inc Type c lectins
US6117977A (en) * 1996-04-24 2000-09-12 Genentech, Inc. Type C lectins
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies

Also Published As

Publication number Publication date
NZ546203A (en) 2009-05-31
JP5808879B2 (en) 2015-11-10
UA91004C2 (en) 2010-06-25
RU2407539C2 (en) 2010-12-27
TW201012472A (en) 2010-04-01
IL174172A (en) 2011-12-29
KR20060088104A (en) 2006-08-03
RU2006112399A (en) 2006-08-10
TW200513262A (en) 2005-04-16
CN1852730B (en) 2012-05-30
AU2004273807B2 (en) 2011-06-09
NO20061306L (en) 2006-06-14
BRPI0414402A (en) 2006-11-14
CN1852730A (en) 2006-10-25
CA2538284C (en) 2015-10-20
IL174172A0 (en) 2006-08-01
CA2538284A1 (en) 2005-03-31
JP2007533618A (en) 2007-11-22
TWI359024B (en) 2012-03-01
AU2004273807A1 (en) 2005-03-31
ZA200602151B (en) 2013-08-28
EP1663290A2 (en) 2006-06-07
EP1663290A4 (en) 2009-07-01
KR101159140B1 (en) 2012-06-22
SG146670A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
CY1108701T1 (en) R-SELECTIN Glycoprotein 1 Regulators.
MX2019011514A (en) TRUNCATED NKG2D CHEMERIC RECEPTORS AND USES OF THE SAME IN IMMUNOTHERAPY WITH NATURAL KILLER CELLS.
CY1119097T1 (en) ANTI-CD40 ANTI-CD40 SILVER LINE FUNCTIONS
MX2019002288A (en) CELLULAR SUSPENSION FOR USE IN THE TREATMENT OF PERIPHERAL ARTERIOPATHY OF THE LOWER EXTREMITIES.
AR120563A1 (en) CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
MX2021010670A (en) CHIMERIC ANTIGEN RECEPTORS DIRECTED TO CD19 AND THEIR USES IN IMMUNOTHERAPY.
AR111625A1 (en) REAGENTS OF OLIGOMERIC PARTICLES AND METHODS OF USE OF THE SAME
UY30732A1 (en) COMPOUNDS FOR THE MODULATION OF THE ACTIVITY OF THE C-FMS AND / OR THE C-KIT AND ITS APPLICABLE USES
MX2022011003A (en) EXPANSION OF GAMMA-DELTA T CELLS RESIDING IN NON-HEMATOPOETIC TISSUE AND USES OF THESE CELLS.
BR112019005633A8 (en) SPECIFIC TCRS FOR HISTOCOMPATIBILITY (H) MINOR HA-1 ANTIGEN AND USES THEREOF
CU20110096A7 (en) COMPOUNDS THAT EXPAND HEMATOPOYETIC MOTHER CELLS
CO6501191A2 (en) CELLULAR MEDIA FOR EXPRESSION OF ADAMTS PROTEIN
MA38308A1 (en) Bispecific antigen binding molecules activating t-lymphocytes
PE20110020A1 (en) IMMUNOMODULATION THROUGH THE USE OF PLACENTA STEM CELLS
EA201591467A1 (en) ANTI-LAG-3 BINDING PROTEINS
PE20152005A1 (en) GLA DOMAINS AS THERAPEUTIC AGENTS
PE20110358A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF BONE DEFECTS WITH PLACENTARY CELL POPULATIONS
ECSP099688A (en) MOLECULES AND METHODS TO MODULATE PRO-PROTEIN
MX2017016486A (en) COMPOSITIONS AND METHODS TO CONTROL VEGETABLE PESTS.
EA201591373A1 (en) MANUFACTURING OF MODIFIED EXTRACELLULAR MATRIX OF TAPE-ENGINEERING NERVOUS TRANSPLANTAS TO RESTORE DAMAGED PERIPHERAL NERVES
MX386373B (en) METHOD FOR PRODUCING NATURAL KILLER (NK) CELLS AND COMPOSITION FOR CANCER TREATMENT.
CL2017001903A1 (en) Novel composition for use in increasing the efficiency of hematopoietic stem cell grafting after transplantation
MX2024004122A (en) Natural killer cells and methods of use thereof.
BRPI0414402A (en) p-selectin glycoprotein binder 1 modulators
ECSP067055A (en) T-CELL DEATH INDUCTIVE EPITHOPES